Tags

Type your tag names separated by a space and hit enter

Induction of pharmacological hypogonadotropism using gonadotropin-releasing hormone agonists in patients undergoing controlled ovarian stimulation.
Gynecol Obstet Invest. 1990; 29(2):132-9.GO

Abstract

Pharmacological hypogonadotropism was induced in 167 women using the gonadotropin-releasing hormone agonists (GnRH-A) buserelin acetate or triptorelin acetate. 84 patients (group 1) began treatment using 1.2 mg/day buserelin acetate intranasally during the follicular phase (days 1-3); 41 patients (group II) began the same treatment, supported by 10 mg medroxyprogesterone acetate for 10 days, during the early luteal phase; 42 patients (group 3) received triptorelin acetate as an intramuscular depot injection, supported by 10 mg medroxyprogesterone acetate for 10 days, during the early luteal phase. Serum luteinizing hormone, follicle-stimulating hormone, oestradiol (E2), prolactin, and testosterone levels were monitored. Pituitary function was assessed by (1) measurement of endogenous luteinizing hormone fluctuation; (2) response to luteinizing hormone releasing hormone administration, and (3) response to oestradiol benzoate (E2 test). Complete pituitary desensitization was only assumed, if all three tests were negative. The LH-RH test and the E2 test were shown to be the most reliable indicator of pituitary function. E2 administration led to further reduction of gonadotropin secretion after pituitary desensitization. The desensitization time was 41.1 +/- 11.7 days in group 1 and was significantly reduced to 20.7 +/- 10.5 days in group 2 (p less than 0.01); a further, non-significant shortening to 15.1 +/- 3.0 days was observed in group 3. Changes in endocrine parameters demonstrated hypogonadotropic hypo-oestrogenism after initial pituitary stimulation.

Authors+Show Affiliations

Department of Obstetrics and Gynaecology, University of Hamburg, FRG.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2139863

Citation

Lindner, C, et al. "Induction of Pharmacological Hypogonadotropism Using Gonadotropin-releasing Hormone Agonists in Patients Undergoing Controlled Ovarian Stimulation." Gynecologic and Obstetric Investigation, vol. 29, no. 2, 1990, pp. 132-9.
Lindner C, Braendle W, Lichtenberg V, et al. Induction of pharmacological hypogonadotropism using gonadotropin-releasing hormone agonists in patients undergoing controlled ovarian stimulation. Gynecol Obstet Invest. 1990;29(2):132-9.
Lindner, C., Braendle, W., Lichtenberg, V., & Bettendorf, G. (1990). Induction of pharmacological hypogonadotropism using gonadotropin-releasing hormone agonists in patients undergoing controlled ovarian stimulation. Gynecologic and Obstetric Investigation, 29(2), 132-9.
Lindner C, et al. Induction of Pharmacological Hypogonadotropism Using Gonadotropin-releasing Hormone Agonists in Patients Undergoing Controlled Ovarian Stimulation. Gynecol Obstet Invest. 1990;29(2):132-9. PubMed PMID: 2139863.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Induction of pharmacological hypogonadotropism using gonadotropin-releasing hormone agonists in patients undergoing controlled ovarian stimulation. AU - Lindner,C, AU - Braendle,W, AU - Lichtenberg,V, AU - Bettendorf,G, PY - 1990/1/1/pubmed PY - 1990/1/1/medline PY - 1990/1/1/entrez SP - 132 EP - 9 JF - Gynecologic and obstetric investigation JO - Gynecol Obstet Invest VL - 29 IS - 2 N2 - Pharmacological hypogonadotropism was induced in 167 women using the gonadotropin-releasing hormone agonists (GnRH-A) buserelin acetate or triptorelin acetate. 84 patients (group 1) began treatment using 1.2 mg/day buserelin acetate intranasally during the follicular phase (days 1-3); 41 patients (group II) began the same treatment, supported by 10 mg medroxyprogesterone acetate for 10 days, during the early luteal phase; 42 patients (group 3) received triptorelin acetate as an intramuscular depot injection, supported by 10 mg medroxyprogesterone acetate for 10 days, during the early luteal phase. Serum luteinizing hormone, follicle-stimulating hormone, oestradiol (E2), prolactin, and testosterone levels were monitored. Pituitary function was assessed by (1) measurement of endogenous luteinizing hormone fluctuation; (2) response to luteinizing hormone releasing hormone administration, and (3) response to oestradiol benzoate (E2 test). Complete pituitary desensitization was only assumed, if all three tests were negative. The LH-RH test and the E2 test were shown to be the most reliable indicator of pituitary function. E2 administration led to further reduction of gonadotropin secretion after pituitary desensitization. The desensitization time was 41.1 +/- 11.7 days in group 1 and was significantly reduced to 20.7 +/- 10.5 days in group 2 (p less than 0.01); a further, non-significant shortening to 15.1 +/- 3.0 days was observed in group 3. Changes in endocrine parameters demonstrated hypogonadotropic hypo-oestrogenism after initial pituitary stimulation. SN - 0378-7346 UR - https://www.unboundmedicine.com/medline/citation/2139863/Induction_of_pharmacological_hypogonadotropism_using_gonadotropin_releasing_hormone_agonists_in_patients_undergoing_controlled_ovarian_stimulation_ L2 - https://www.karger.com?DOI=10.1159/000293319 DB - PRIME DP - Unbound Medicine ER -